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Over the past several years a new era for patients requiring anticoagulation has arrived. The approval of new target
specific oral anticoagulants offers practitioners several advantages over traditionally used vitamin K antagonist
agents including predictable pharmacokinetics, rapid onset of action, comparable efficacy and safety, all without
the need for routine monitoring. Despite these benefits, hemorrhagic complicates are inevitable with any
anticoagulation treatment. One of the major disadvantages of the new oral anticoagulants is lack of specific
antidotes or reversal agents for patients with serious bleeding or need for urgent surgery. As use of the new target
specific oral anticoagulants continues to increase, practitioners will need to understand both the
pharmacodynamics and pharmacokinetic properties of the agents, as well as, the available literature with use of
non-specific therapies to reverse anticoagulation. Four factor prothrombin complex concentrates have been
available for several years in Europe, and recently became available in the United States with approval of Kcentra.
These products have shown efficacy in reversing anticoagulation from vitamin K antagonists, however their
usefulness with the new target specific oral anticoagulants is poorly understood. This article will review the
properties of dabigatran, rivaroxaban and apixaban, as well as the limited literature available on the effectiveness of
prothrombin complex concentrates in reversal of their anticoagulant effects. Additional studies are needed to more
accurately define the role of prothrombin complex concentrates in patients with life threatening bleeding or who
require emergent surgery, as current data is both limited and conflicting.Introduction
Anticoagulation is a routine intervention for the manage-
ment of arterial and venous thromboembolic events across
a wide variety of clinical situations. Despite the robust
clinical history of anticoagulant development and clinical
use, as recently as 2009 vitamin K antagonists (VKAs)
had been the only oral anticoagulants available for the
prevention and treatment of thrombosis. The availability
of new target specific oral anticoagulants (TSOACs) has
now changed that paradigm. The introduction of the
direct thrombin inhibitor (DTI) dabigatran, as well as the
factor Xa inhibitors rivaroxaban and apixaban represent
potentially attractive alternatives to VKAs. The TSOACs
offer several advantages over VKAs including predictable
pharmacokinetics, rapid onset of action, and comparable
efficacy and safety. The pharmacokinetic advantages
allow for fixed dosing, and mitigate the need for routine* Correspondence: katrina.babilonia@uchealth.org
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article, unless otherwise stated.laboratory monitoring or the need for bridging in the
perioperative setting. A number of recent clinical trials
have resulted in the Food and Drug Administration
(FDA) approval of dabigatran, rivaroxaban and apixaban
for stroke prevention in nonvalvular atrial fibrillation
(AF) [1-3]. Rivaroxaban is also FDA approved for the
prevention of venous thromboembolism (VTE) after
orthopedic surgery, and very recently was approved for
treatment of VTE [4]. The TSOACs also have been ap-
proved for a variety of indications by various accrediting
bodies around the world (Table 1). There is ongoing
research investigating the use of TSOACs for VTE
prophylaxis in hospitalized medically-ill patients, and
patients with acute coronary syndrome [5-7]. As the
U.S. population ages, and research continues, it is likely
that these TSOACs will be prescribed for more FDA
approved, as well as off-label uses.
Despite the many favorable attributes that TSOACs
possess when compared to VKAs, they present unique
clinical challenges of their own. As such, it is unlikely
that TSOACs will replace VKAs in all patients. TheCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Current approval of the NOACs
FDA Approval EMA Approval
Dabigatran -Stroke prevention in AF -VTE prevention after
orthopedic surgery,
-Stroke prevention in AF




-Stroke prevention in AF
- VTE treatment
Apixaban -Stroke prevention in AF -VTE prevention after
orthopedic surgery
-Stroke prevention in AF
EMA = European Medicines Agency, AF = Non- valvular Atrial Fibrillation,
VTE = Venous Thromboembolism to include Deep vein thrombosis and
Pulmonary Embolism.
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may present difficult challenges for clinicians in both the
ambulatory and acute care environments. All of the
TSOACs generally share similar rates of major bleeding
when compared to VKAs, with specific agents showing re-
ductions in bleeding rates for specific disease states [8].
Differences in types of bleeding may be observed though,
with intracranial hemorrhage lower and GI bleeding gen-
erally higher as compared to VKAs. (1–3). However,
bleeding risk is not zero, and management of patients who
bleed while on a TSOAC is complicated by the lack of ef-
fective methods for laboratory monitoring, and emergent
reversal of these medications remain unavailable or poorly
understood. As prescribing and use of TSOACs increase,
it will be increasingly important for clinicians to under-
stand the pharmacokinetic/pharmacodynamic aspects of
individual agents, as well as available evidence regarding
the management of bleeding.Mechanism of action and pharmacokinetics
Dabigatran is a reversible inhibitor of factor IIa (thrombin)
that binds directly to the active site on the thrombin
molecule. Dabigatran is available as a prodrug, dabiga-
tran etexilate, which is rapidly converted to the active
drug dabigatran upon oral administration. Peak plasma
concentrations occur within 1–3 hours, with a half-life
of 12–14 hours in patients with normal kidney function
[9]. Plasma concentration has been shown to correlate
directly with anticoagulant effect [10]. Dabigatran is
predominately excreted unchanged by the kidneys
(80%). In patients with a creatinine clearance (CrCl) less
than 30 ml/min the half-life increases to approximately
27 hours [11]. Dabigatran does not interact with the
cytochrome P450 enzymes; however it is a substrate for
p-glycoprotein and is not devoid of potential drug-drug
interactions.Rivaroxaban is a reversible inhibitor of both free and
clot bound factor Xa. Upon oral ingestion it is rapidly
absorbed with peak plasma concentrations occurring in
approximately 2–4 hours. Plasma concentration corre-
lates directly with anticoagulant effect. Renal function is
important in elimination with one-third of the parent
compound eliminated unchanged in the urine, one-third
is eliminated in the urine as inactive metabolite, and the
remaining one-third is eliminated in the feces [12].
Enough parent compound is cleared through the kidneys
such that with CrCl greater than 80 ml/min the half-life
of rivaroxaban is 8.3 hours, increasing to 9.5 hours in
individuals with CrCl less than 30 ml/min [12]. Rivarox-
aban does have significant liver metabolism, specifically
through Cytochrome P450 3A4, and is also a substrate
of p- glycoprotein. As such, potential drug-drug interac-
tions must be accounted for. Apixaban is also a reversible
inhibitor of both free and clot bound factor Xa. Peak
plasma levels are achieved 1–3 hours after ingestion, and
half-life is 10–14 hours in patients with normal renal func-
tion. Like dabigatran and rivaroxaban, plasma concentra-
tions correlate directly with anticoagulant effect. Apixaban
has similar characteristics to rivaroxaban in that 25% of
the parent compound is cleared through the kidneys, it
undergoes significant hepatic metabolism through cyto-
chrome P450 3A4, and is a substrate for p-glycoprotein.
Reduced renal function and drug-drug interactions also
have the potential to alter the expected pharmacokinetic
and pharmacodynamics response [13]. Table 2 compares
the TSOACs and their pharmacokinetics.
When prescribed appropriately, few patients should ex-
perience clinically significant bleeding while on TSOAC
therapy. When it does occur however, clinicians need to
have an appreciation for the mechanisms of action, clear-
ance, and half-lives of agents to properly manage the situ-
ation. While the TSOACs generally produce a much more
consistent dose–response as compared to oral VKAs,
there are sources of potential pharmacokinetic variability
that are important to consider when challenged with a
patient who may be bleeding in the setting of TSOACs
exposure. One drawback for the TSOACs is the lack of
a readily available and reliable coagulation assay to provide
quantitative information on the level of anticoagulation.
As such, clinicians are required to make vital decisions
with imprecise data. An in depth discussion of the impact
of TSOACs on available coagulation assays is beyond the
scope of this review and clinicians are referred to several
recent reviews on this topic [14,15].
Strategies for anticoagulation reversal
Patients presenting with anticoagulant-related bleeding
while receiving TSOAC therapy should ideally be man-
aged according to a pre-determined approach as deter-
mined by institutional guidelines. Details of this approach
Table 2 TSOAC Pharmacokinetics
Dabigatran Rivaroxaban Apixaban
Target Factor IIa Factor Xa Factor Xa
Dosage Form capsule tablet tablet
Bioavailability 6% 60-80% 50-85%
Time to Peak 1-2 hours 2-4 hours 1-3 hours
Metabolism Conjugation; No CYP
involvement
Oxidation via CYP3A4 Oxidation via CYP3A4
Renal Excretion 80% 33% 25%
Substrate of p- glycoprotein? Yes Yes Yes
FDA approved dosing for stroke
prevention in a- fib
150 mg twice daily for 20 mg by mouth once daily
for patients CrCL > 50 ml/min
5 mg by mouth twice daily
patients CrCL > 30 ml/min 15 mg by mouth once daily 2.5 mg by mouth twice daily for patients with 2
or more of the following: Age > 80, weight < 60 kg
or Serum Cr > 1.575 mg by mouth twice
daily for CrCL 15–30 ml/min
for patients with CrCL
15-50 ml/min
FDA approved dosing for VTE
prevention in hip
N/A 10 mg once daily for patients




FDA approved N/A 15 mg by mouth twice daily N/A
dosing for {1) treatment of acute
DVT or PE, or {2) long term
prevention of
for 21 days, then 20 mg once
daily for patients with
CrCL > 30 ml/min
recurrent DVTfPE 20 mg once daily for patients
with CrCL > 30 ml/min
CrCl = Creatinine Clearance, CYP = Cytochrome P450.
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specific agent, the urgency of the clinical situation as
well as the severity of bleeding. Options may include
(1) observation and withholding anticoagulant therapy
alone; (2) administering a specific reversal agent if one
is available; (3) administration of supplemental clotting
factors either via fresh frozen plasma (FFP) or prothrom-
bin complex concentrates (PCCs); (4) Administration of
prohemostatic agents such as activated prothrombin
complex concentrates (aPCC or FEIBA) or recombinant
factor VIIa (rFVIIa). Any of these interventions should
always be preceded by appropriate supportive and symp-
tomatic treatment, including mechanical compression or
surgical intervention.
Due to their relatively short half-lives, supportive care
and observation may be adequate for the majority of
patients experiencing bleeding while on TSOAC therapy.
Provided the patient has adequate renal function and/or
no significant drug-drug interactions, it would be expected
that clinically significant plasma concentrations of TSOAC
therapy would be absent 24–36 hours after the last ad-
ministered dose. Given each of the new TSOAC agents
have no available antidote, there has been significant
considerations in the use of either factor replacement
therapy, or prohemostatic agents in the management of
bleeding patients. However, as will be subsequentlydiscussed there is little information to guide the clinician
on the best approach with these agents. The presence of
one of the potential factors listed in Table 3 may be helpful
in recognizing whether bleeding may be due to potential
over-anticoagulation, and whether aggressive interventions
such as administration of a pro-hemostatic agent may be
warranted.
Prothrombin Complex Concentrates (PCC)
Prothrombin Complex Concentrates (PCC) are a con-
centrated plasma product that contains clotting factors
in varying amounts. Formulations can include 3 factor
products (II, IX and X) or 4 factor products (II, VII, IX
and X). Dosing of PCC products is expressed as units of
factor IX [16]. The factors provided by PCC products
are generally not activated and require activation by the
clotting cascade. There is one activated PCC (aPCC)
product available, FEIBA, which contains activated Factor
VII and inactivated forms of Factors II, IX and X [17].
Available inactive PCC products contain varying amounts
of factors II, VII, IX and X. Some products may also con-
tain coagulation inhibitors such as heparin, antithrombin,
protein C, protein S and protein Z to mitigate thrombotic
risk [18]. PCC formulations are listed in Table 4.
PCCs were originally created as a replacement product
for Factor IX in Hemophilia B patients. These products
Table 3 Metabolism of the TSOACs
Dabigatran Rivaroxaban Apixaban
Renal Impairment 6 fold higher exposure when CrCL
10–30 ml/min
1.6 fold higher exposure when CrCL 15-29 1.44 fold higher exposure when CrCL
15-29
Age Age > 75 = 30% increase in trough
concentrations
Mean AUC 1.5 fold higher in age > 65 Mean AUC 1.3 fold higher in age > 65
Hepatic
Impairment
N/A 2.3 fold increase exposure in Child-Pugh B N/A
Drug-drug
interactions
Avoid strong inhibitors or inducers
of p-glycoprotein
Avoid strong inhibitors of p-glycoprotein
and CYP 3A4
Avoid strong inhibitors of p-glycoprotein
and CYP 3A4
AUC = Area under the curve CrCL = Creatinine Clearance CYP = Cytochrome P450.
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apy [19]. PCC dosing for anticoagulation reversal varies
from 25–50 IU/kg. Several studies have demonstrated
PCC efficacy in reversal of VKA anticoagulation for cases
of emergent bleeding and emergent surgery [20-23]. Stud-
ies comparing effectiveness of PCC to fresh frozen plasma
(FFP) indicate that PCC products provide a more rapid
decrease in INR values as compared to FFP [20-23]. The
2012 CHEST Antithrombotic Guidelines recommend the
use of PCC over FFP for patients with life-threatening
bleeds while on VKA therapy [24]. However, this rec-
ommendation was Grade 2C, which indicates it is a
weak recommendation with low quality evidence [24].
PCCs have also been evaluated and may be beneficial
for off label use to restore hemostasis in excessive
bleeding following surgery and major trauma [25,26].
While FFP and vitamin K have been the mainstay of
VKA reversal and management of bleeding, these therap-
ies are less likely to be efficacious in bleeding associated
with TSAOCs. The goal of anticoagulation reversal with
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Beriplex 20-48 10-25 20-31 22-6
Cofact 30 13 23 26
Kcentra 19-40 10-25 20-31 25-5
Octaplex 31 16 22 24
Activated PCC
FEIBA* 1.3 IU/IU 0.9 IU/IU 1.4 IU/IU 1.1 IU
aAll concentrations are approximate and vary from one lot to another.
NMT = not more than, IU = international units.
*IU/IU = IU/FEIBA unit.or factor Xa. FFP contains much lower amounts of clot-
ting factors II, VII, IX and X when compared to PCC
products. Therefore, the amount of FFP required to ad-
minister an equivalent factor replacement dose received
in PCC products would be 8–16 units of FFP [27]. The
amount of FFP and volume required to administer the
reversal dose would likely not be feasible in urgent
bleeding scenarios. In addition, patients with cardiac,
pulmonary and renal issues may not be able to tolerate
such large amounts of volume. PCC products may offer
a number of additional advantages over FFP. FFP is fre-
quently available only via the hospital blood bank and
must be thawed prior to administration. The time in-
volved with procurement and administration of agent
may be problematic. PCC products go through at least
one viral inactivation step to reduce the risk of viral
pathogen transmission [28]. Finally, unlike FFP, PCC’s
are free of leukocytes, so they are less likely to cause
transfusion related acute lung injury (TRALI) or infu-
sion reactions [28]. PCC product labeling does include
a warning of potential arterial and venous thromboticProtein levels ( IU/ml) Other
C S Z ATIII Heparin




NA NA NA None None
0 22-31 17-19 Yes Yes Yes
4 21 Yes Yes None
1 21-41 12-23 No Yes Yes
12 24 Yes No Yes
/IU 1.1 IU/IU NA NA No No
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formulations differ greatly from preparations used in the
1970-80’s, and generally are thought to have a lower
thrombosis risk [28]. For example, many of today’s PCC
formulations contain coagulation inhibitors such as hep-
arin, antithrombin, protein C, protein S and protein Z
which allows for more balanced replacement of procoagu-
lants factors and anticoagulants proteins [28]. Evidence
suggests that the primary determinant of the thrombotic
risk associated with PCC use is accumulation of factor II,
which is associated with large or frequent dosing [28].
PCC use in patients who are predisposed to thrombotic
complications (i.e. patients who require outpatient antic-
oagulation therapy) makes it difficult to identify if throm-
botic events are attributable to PCC use or to patient
comorbidities [28]. Therefore, practitioners considering
anticoagulation reversal therapies should weigh the risk
of thrombotic complications from treatment with PCC
against the need for rapid correction of coagulopathy.
Dabigatran reversal
Animal studies
In an in-vivo animal study, rats received high doses of
dabigatran (30 mg/kg) or placebo via gastric lavage. The
reversal effects of PCC (Beriplex, Octaplex), activated re-
combinant Factor VII (rVIIa) (Novoseven) and activated
PCC (FEIBA) were evaluated using tail bleeding times and
coagulation parameters including thrombin time (TT),
activated partial thromboplastin time (aPTT), prothrobin
time (PT) and ecarin clotting time (ECT). Bleeding times
were increased from 171 sec in control subjects to 495 sec
in subjects receiving dabigatran. All coagulation labs were
prolonged 3–5 fold baseline following dabigatran adminis-
tration. Administration of 35 IU/kg Beriplex, 40 IU/kg
Octaplex, 0.5 mcg/kg rVIIa or 100 IU/kg FEIBA com-
pletely reversed dabigatran associated bleeding times to
baseline within 5 min of IV administration. This effect
was maintained for the 2 hour study period. Despite the
effects on bleeding time, coagulation parameters including
TT, aPTT and ECT remained prolonged after administra-
tion of the PCC products. Only PT was reversed to base-
line levels [30].
Another in vivo rat study evaluated rFVIIa (Novoseven)
or activated PCC (FEIBA) on bleeding times and aPTT
following administration of supratherapeutic doses of
dabigatran. Bleeding times were significantly increased
with dabigatran compared to controls, with 1455 sec vs
145 sec. Administration of rFVIIa (0.1 or 0.5 mcg/kg) or
FEIBA (50 u/kg or 100 u/kg) significantly decreased
bleeding times to 186 sec and 135 sec with rFVIIa, or
146 sec and 174 sec with FEIBA. Effects on coagulation
assays were noted again to be discordant with effects on
bleeding. aPTT was dose dependently decreased by rFVIIa
but not by FEIBA [31].An in vivo rabbit study evaluated the effect of 4-Factor
PCC (Beriplex) in rabbits treated with dabigatran who
then underwent kidney incision. Subjects received dabi-
gatran 0.4 mg/kg, followed by administration of saline or
PCC with doses of 20 u/kg, 35 u/kg or 50 u/kg. Blood
loss in control subjects ranged from 1–7.2 ml. Adminis-
tration of dabigatran increased bleeding to 15–46 ml.
Blood loss was significantly diminished with increasing
PCC doses, with a decrease in bleeding volume of
5.44 ml per 10 IU/kg increment increase in PCC dose.
The 50 IU/kg PCC dose decreased blood loss to vol-
umes similar to that seen in the control subjects. Time
to hemostasis was 20 min in patients treated with dabi-
gatran followed by saline. This time was also decreased
with increasing doses of PCC, falling to a median of
5.7 min in the highest PCC dose (50 u/kg) group [32].
Human studies
In an ex vivo study, 10 healthy subjects received a single
dose of dabigatran 150 mg. Blood samples were collected
just prior to drug administration and then 2 hours after to
assess peak concentrations. Reversal agents administered
included 4-Factor PCC (Kanokad), rFVIIa (Novoseven), or
activated PCC (FEIBA). Addition of 4-Factor PCC (25 u/kg)
and FEIBA (80 u/kg) to blood samples resulted in a large
increase in thrombin generation to above baseline levels.
However, increased thrombin generation was not seen
with rFVII [33].
Another study evaluated the effect of 4-Factor PCC
(Cofact) on 12 healthy adults who had been administered
dabigatran 150 BID for 2 and 1/2 days. The patients had
baseline coagulation labs including aPTT, ECT and TT
drawn, then received PCC (50 u/kg). Coagulation labs
were collected and assessed at various intervals over the
next 24 hours. PCC had no effect on coagulation assays
at any interval of the study period [34].
Case reports with excessive response to dabigatran
A 72 y/o female was started on dabigatran 220 mg daily
for prophylaxis following total hip replacement (THR).
Two days later, the patient developed dyspnea, hypotension,
tachycardia and anemia. She received 2 units of packed
red blood cells (PRBC’s) and was thought to have a pul-
monary emboli (PE). Dabigatran was discontinued and the
patient was started on enoxaparin 0.7 mg/kg BID. PE was
later ruled out and enoxaparin was discontinued. The pa-
tients clinical status continued to worsen with hypovol-
emic shock and acute renal failure. A laparotomy was
performed which revealed ischemic lesions requiring
bowel resection. Prior to surgery (2 days after discontinu-
ation of dabigatran, 1 day after discontinuation of enoxa-
parin) PT > 60 sec and aPTT > 150 sec. The patient
received 22 u PRBC, 26 u FFP, 40 u/kg of PCC (Kaskadil),
66 mcg/kg of rFVIIa (Novoseven), 1.5 gm of figrinogen
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these measures, the patients PT and aPTT remained
elevated. The patient died 2 hours after surgery [35].
A 67 year old male taking dabigatran 150 mg BID for
atrial fibrillation experienced a life threatening bleed
during a cardiac ablation procedure. The patient received
his last dose of dabigatran 8 hours prior to the procedure.
A trans-septal perforation occurred resulting in massive
blood losses that exceeded 3 L via the pericardial window.
The patient received FFP, protamine, and packed red
blood cells with no reduction in bleeding. A low dose
(26 u/kg) of activated PCC (FEIBA) was infused over
15 min. Signs of hemostasis were observed within mi-
nutes of initiation of the infusion. Bleeding had stopped
by the completion of the PCC infusion [36].Rivaroxaban reversal
Animal studies
In a rabbit study, subjects were randomized into 4
groups; control, rivaroxaban + saline, rivaroxaban + rFVIIa
150 mcg/kg, or rivaroxaban + PCC 40 u/kg (Kaskadil).
Hepatosplenic blood loss was significantly increased in
the rivaroxaban group as compared to controls, 17 gm
vs 7 gm respectively. Neither rFVIIa or PCC reduced
blood loss, 15 gm vs 19.5 gm, respectively. Additionally,
laboratory coagulation tests, such as PT and aPTT, were
increased significantly in the rivaroxaban treated group
compared to controls. Recombinant FVIIa and PCC
normalized aPTT and only partially corrected the PT.
Neither reduced blood loss [37].
A rat experiment evaluated mesenteric bleeding times
in subjects that had received rivaroxaban. Subjects were
randomized to receive inactive PCC (25 u/kg, 50 u/kg),
activated PCC (aPCC) (50 u/kg, 100 u/kg) or rFVIIa
(100 mcg/kg, 400 mcg/kg). Administration of inactive
PCC 50 u/kg significantly reduced bleeding times, how-
ever bleeding times with the 25 u/kg dose were similar
to controls. Activated PCC reduced bleeding times at
both doses. There was not an increased effect on bleed-
ing times associated with use of the higher 100 u/kg
aPCC dose. Finally, rFVIIa significantly reduced bleed-
ing times at 400 mcg/kg dose. The 100 mcg/kg dose also
decreased bleeding time, but it was not statistically
significant [38].
In a baboon study, subjects received intravenous infu-
sion of rivaroxaban, followed by an infusion of either
aPCC 50 u/kg (FEIBA) or 210 mcg/kg rFVIIa (Novose-
ven). Upon completion of the aPCC infusion bleeding
times had normalized. However 20 min after completion
of the infusion, bleeding time increased to 1.7 times nor-
mal. In subjects treated with rFVIIa a 34% reduction in
bleeding times were observed, but this did not reach
statistical significance [38].Human studies
In the above mentioned ex vivo human study, the patients
underwent a 2 week wash out period and were then ad-
ministered 20 mg of rivaroxaban in a single dose. PCC
(Kanokad), aPCC (FEIBA) or rFVIIa (Novoseven) were
once again added to blood samples and evaluated ex vivo.
In this case, PCC and rFVIIa only partially increased peak
thrombin generation in samples. Activated PCC normal-
ized thrombin generation [33].
Rivaroxaban was also evaluated in the previously
discussed trial in which 12 healthy adults received
therapeutic doses of rivaroxaban for 2 and ½ days,
followed by administration of 50 u/kg of PCC (Cofact).
In this case, PT was normalized almost immediately.




An in vivo study evaluated the effect of rFVII (Novoseven),
PCC (Kanokad) and fibrinogen (Clottafact) in rabbits ad-
ministered apixaban [39]. Subjects were given apixaban
0.4 mg/kg bolus, with 0.6 mg/kg/hr infusion then random-
ized to receive, rFVII 240 mcg/kg, PCC 60 IU/kg, or fi-
brinogen 300 mg/kg. Apixaban significantly increase
hepatosplenic blood loss and bleeding times compared to
control, 11.6 gm and 126.4 sec with apixaban vs 8.3 gm
and 70.8 sec with control. Administration of either PCC
or rFVII did not decrease hepatosplenic blood loss (11.8
gm and 12.2 respectively.) However, both PCC and rFVII
were found to partially reverse bleeding time to 101.1 sec
and 83.5 sec, respectively. Fibrinogen appeared to increase
both blood loss and bleeding time in apixaban treated
rabbits to 19.2 gm and 154.2 sec. However, paradoxically
fibrinogen improved clot firmness and increased endogen-
ous thrombin potential (ETP). The authors proposed that
this paradoxical effect may be attributed to the numerous
effects fibrin can exert on thrombin. Therefore, thrombin
activity may not reflect it’s true coagulant potential. Apixa-
ban modestly increased PT, but had no effect on aPTT.
Only rFVII normalized prolonged PT values, PCC and
fibrinogen had no effect [39].
Human studies
There were no studies found that evaluated reversal strat-
egies for apixaban anticoagulation in humans.
Discussion
Patients with over anticoagulation or bleeding secondary
to decreased levels of circulating clotting factors (as seen
with VKA therapy) respond to factor replacement with
FFP, PCC and vitamin K. Unfortunately, these strategies
are less efficacious in patients receiving target specific
inhibition of clotting factors as seen with direct thrombin
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reversal is not only to replace clotting factors, but to
overwhelm the direct inhibition of factors in the latter
phases of the coagulation cascade [27].
The pharmacokinetic profiles of the TSOACs differs
greatly from that seen with VKA’s. Elimination of dabiga-
tran, and to a lesser extent rivoraxaban and apixaban, is
predominately renal [40-42]. This can be advantageous
in patients with preserved renal function experiencing
minor bleeding or requiring surgery, as a strategy of hold-
ing doses or delaying procedures may be sufficient. In
addition, removal of dabigatran via hemodialysis may also
provide benefit in patients with decreased renal clearance
of the agent [40]. Unfortunately, cessation of the anti-
coagulant agent or initiation of hemodialysis may not be
sufficient or feasible in patients with major bleeding or
requiring emergent surgery.
One major disadvantages of the TSAOCs is the lack of
specific antidotes for patients with excessive anticoagula-
tion, major bleeding, or need for emergent surgery. Spe-
cific antidotes are in development for both the oral direct
thrombin inhibitors and factor Xa inhibitors. A monoclo-
nal antibody that neutralizes dabigatran is in clinical trials.
Initial in vitro and ex vivo studies have demonstrated
complete inhibition of dabigatran anticoagulant activity
[43]. A reversal product is also in development for factor
Xa inhibitor anticoagulants [44,45]. This product contains
an inactive factor Xa molecule that can bind to factor Xa
inhibitors (such as rivaroxaban or apixaban) and decrease
their anticoagulant effect [44,45]. Currently, the product is
entering into Phase II clinical trials [45].
The lack of reliable monitoring assays further compli-
cates scenarios in which urgent anticoagulation reversal
is required. The TSAOCs will prolong traditionally used
coagulation assays, such as PT and aPTT, however sen-
sitivity can vary greatly based on agent or assay manu-
facturer and lot [46,47]. In addition, normalization of
coagulation assays in animal models did not always
correlate with improvement in bleeding [27,38].
Conclusions
Dabigatran
Hemodialysis should be considered in patients with im-
paired renal function who require reversal of dabigatran
for major bleeding or surgical procedures when avail-
able. PCC use decreased bleeding times in both rats and
rabbits who had received dabigatran [30,32]. The avail-
able studies in human did not evaluate bleeding times,
but instead focused on coagulation assays (aPTT, ECT,
TT) or measures of thrombin generation [34,33]. These
studies demonstrated that PCC was able to significantly
increase thrombin generation in in vitro blood samples
containing dabigatran, but did not correct coagulation
assays commonly used to assess level of anticoagulationin vivo [34,33]. Activated PCC (FEIBA) corrected bleed-
ing times in two rat models and proved to significantly
increase thrombin generation in vitro in humans [30,31,33].
Based on these results, use of 4-factor PCC or aPCC
would be reasonable choices for urgent reversal of patients
with dabigatran associated major bleeding or need for
emergent surgery. Activated PCC may carry a higher
risk of thrombosis, and therefore may be considered as
an alternative if a 4-factor PCC is not available.
Rivaroxaban
PCC use did not decrease hepatosplenic bleeding in rab-
bits treated with rivaroxaban, but at high doses (50 u/kg)
was able to decrease mesenteric bleeding in rats [37,38].
In human studies, PCC completely normalized both PT
and endogenous thrombin potential (ETP) immediately
following infusion, however it only partially increased peak
thrombin generation in an ex vivo human model [34,33].
Activated PCC significantly improved bleeding times in
rats and baboons treated with rivaroxaban, but in the ba-
boon model the bleeding correction was not sustained
[38]. In the human ex vivo evaluation aPCC normalized
thrombin generation [33]. Based on this available evi-
dence, use of either a 4-factor PCC or aPCC would be rea-
sonable choices for reversal of rivaroxaban. The evidence
supporting aPCC may be slightly more favorable, but con-
sideration of the increased thrombosis risk for activated
factor products must also be considered.
Apixaban
PCC use did not decrease bleeding volumes, but was able
to partially decrease bleeding times in rabbits. PCC was
also not able to normalize elevated PTs associated with
apixaban administration [39]. Despite the limited amount
of data with apixaban reversal, it may be rational to apply
the same reversal strategies used for rivaroxaban to apixa-
ban based on their similar mechanism of action.
Additional studies are needed to evaluate the effective-
ness of factor replacement for reversal of oral anticoagu-
lants and the risk of thrombosis associated with these
therapies.
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